These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 20702972)

  • 1. [Pharmacological, pharmacokinetic, and clinical profile of palonosetron hydrochloride (ALOXI I.V. Injection 0.75 mg), a novel antiemetic 5-HT3-receptor antagonist].
    Ajioka H; Morita F; Akizawa Y; Yoshida K; Kitamura R; Takimoto H
    Nihon Yakurigaku Zasshi; 2010 Aug; 136(2):113-20. PubMed ID: 20702972
    [No Abstract]   [Full Text] [Related]  

  • 2. Palonosetron.
    Siddiqui MA; Scott LJ
    Drugs; 2004; 64(10):1125-32; discussion 1133-4. PubMed ID: 15139789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Theoretical evaluation of antiemetic effects of 5-HT3 receptor antagonists for prevention of vomiting induced by cisplatin.
    Nakamura H; Yokoyama H; Takayanagi R; Yoshimoto K; Nakajima A; Okuyama K; Iwase O; Yamada Y
    Eur J Drug Metab Pharmacokinet; 2015 Mar; 40(1):39-44. PubMed ID: 24470169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palonosetron (Aloxi) for prevention of nausea and vomiting due to cancer chemotherapy.
    Med Lett Drugs Ther; 2004 Mar; 46(1179):27-8. PubMed ID: 15057189
    [No Abstract]   [Full Text] [Related]  

  • 5. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB
    Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting.
    Fabi A; Malaguti P
    Expert Opin Pharmacother; 2013 Apr; 14(5):629-41. PubMed ID: 23414148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting.
    Yeh YC; McDonnell A; Klinger E; Fowler B; Matta L; Voit D; Reddy P
    J Oncol Pharm Pract; 2011 Sep; 17(3):179-85. PubMed ID: 20452991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting.
    Ruhlmann C; Herrstedt J
    Expert Rev Anticancer Ther; 2010 Feb; 10(2):137-48. PubMed ID: 20131990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palonosetron. RS 25259, RS 25259 197.
    Drugs R D; 1999 Oct; 2(4):251-2. PubMed ID: 10659403
    [No Abstract]   [Full Text] [Related]  

  • 10. Review of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomiting.
    Lorusso V; Karthaus M; Aapro M
    Future Oncol; 2015; 11(4):565-77. PubMed ID: 25360998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical data.
    Natale JJ; Spinelli T; Calcagnile S; Lanzarotti C; Rossi G; Cox D; Kashef K
    J Oncol Pharm Pract; 2016 Jun; 22(3):485-95. PubMed ID: 25998320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of netupitant and palonosetron in chemotherapy-induced nausea and vomiting.
    Abramovitz RB; Gaertner KM
    J Oncol Pharm Pract; 2016 Jun; 22(3):477-84. PubMed ID: 25914408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of palonosetron: emerging data distinguishing it as a novel 5-HT(3) receptor antagonist for chemotherapy-induced nausea and vomiting.
    Saito M; Tsukuda M
    Expert Opin Pharmacother; 2010 Apr; 11(6):1003-14. PubMed ID: 20307224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exposure-Response of Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients.
    Wang J; Mehrotra N; Kim I; Lee SC; Sohrabi F; He R; Mulberg A; Sinha V; Ahn HY; Bashaw D; Griebel D
    J Pediatr Gastroenterol Nutr; 2016 Oct; 63(4):412-6. PubMed ID: 26913757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist.
    Navari RM
    Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1577-86. PubMed ID: 19929251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis of antiemetic effect of various dosage regimens of azasetron hydrochloride based on 5-HT3 receptor occupancy of serotonin].
    Yamada Y; Fujita M; Okuyama K; Takayanagi R; Ozeki T; Yokoyama H; Iga T
    Yakugaku Zasshi; 2007 Feb; 127(2):353-7. PubMed ID: 17268155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological characterization of RS 25259-197, a novel and selective 5-HT3 receptor antagonist, in vivo.
    Eglen RM; Lee CH; Smith WL; Johnson LG; Clark R; Whiting RL; Hegde SS
    Br J Pharmacol; 1995 Feb; 114(4):860-6. PubMed ID: 7773547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palonosetron Prevents Highly Emetogenic Chemotherapy-induced Nausea and Vomiting in Oral Cancer Patients.
    Sento S; Kitamura N; Yamamoto T; Nakashiro K; Hamakawa H; Ibaragi S; Sasaki A; Takamaru N; Miyamoto Y; Kodani I; Ryoke K; Mishima K; Ueyama Y;
    Anticancer Res; 2017 Dec; 37(12):6977-6981. PubMed ID: 29187483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II randomised study to evaluate the efficacy of aprepitant plus palonosetron for preventing delayed-phase CINV associated with TC therapy in gynaecological cancer.
    Sugimori Y; Ota T; Ujihira T; Ishiguro T; Ogishima D
    J Obstet Gynaecol Res; 2017 Sep; 43(9):1454-1459. PubMed ID: 28952201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of palonosetron versus other serotonin 5-HT3 receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapy.
    Kim KI; Lee DE; Cho I; Yoon JH; Yoon SS; Lee HS; Oh JM
    Ann Pharmacother; 2012 Dec; 46(12):1637-44. PubMed ID: 23170032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.